Serial Number 97686104
Registration 7484584
700

Registration Progress

Application Filed
Nov 21, 2022
Under Examination
Approved for Publication
Jun 11, 2024
Published for Opposition
Jun 11, 2024
Registered
Aug 27, 2024

Basic Information

Serial Number
97686104
Registration Number
7484584
Filing Date
November 21, 2022
Registration Date
August 27, 2024
Published for Opposition
June 11, 2024
Drawing Code
2

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 27, 2024
Registration
Registered
Classes
005 042 044

Rights Holder

Verona Pharma PLC

99
Address
One Central Square
Cardiff CF101FS
GB

Ownership History

Verona Pharma PLC

Original Applicant
99
Cardiff GB

Verona Pharma PLC

Owner at Publication
99
Cardiff GB

Verona Pharma PLC

Original Registrant
99
Cardiff GB

Legal Representation

Attorney
Robert B.G. Horowitz, Esq.
USPTO Deadlines 2 active
Deadline Type Event Code Deadline Date Days Until Priority Extension Available
MAINTENANCE
Section 8 (6-Year) Declaration Due (Based on registration date 2024-08-27)
R.PRA Aug 27, 2030 1877 days Critical No
MAINTENANCE
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2024-08-27)
R.PRA Aug 27, 2034 3338 days Critical No
Next deadline: Section 8 (6-Year) Declaration Due (Based on registration date 2024-08-27) on August 27, 2030 (1877 days)

Application History

22 events
Date Code Type Description
Apr 2, 2025 ASCK I ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Aug 27, 2024 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 27, 2024 R.PR A REGISTERED-PRINCIPAL REGISTER
Jun 11, 2024 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 11, 2024 PUBO A PUBLISHED FOR OPPOSITION
May 22, 2024 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 9, 2024 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 26, 2023 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 26, 2023 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 25, 2023 ALIE A ASSIGNED TO LIE
May 25, 2023 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 22, 2023 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
May 22, 2023 GNSL S LETTER OF SUSPENSION E-MAILED
May 22, 2023 CNSL R SUSPENSION LETTER WRITTEN
May 22, 2023 XAEC I EXAMINER'S AMENDMENT ENTERED
May 22, 2023 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 22, 2023 GNEA F EXAMINERS AMENDMENT E-MAILED
May 22, 2023 CNEA R EXAMINERS AMENDMENT -WRITTEN
May 22, 2023 DOCK D ASSIGNED TO EXAMINER
Dec 13, 2022 MDSC E NOTICE OF DESIGN SEARCH CODE E-MAILED
Dec 12, 2022 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 24, 2022 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 005
Pharmaceutical preparations and substances for the treatment of respiratory conditions and disease, namely, chronic obstructive pulmonary disease, cystic fibrosis and asthma
Class 042
Scientific research for medical purposes, namely, the research and development of pharmaceutical preparations for the treatment of respiratory conditions and disease, in particular, chronic obstructive pulmonary disease, cystic fibrosis and asthma
Class 044
Medical treatment services in the field of respiratory conditions and disease, namely, chronic obstructive pulmonary disease, cystic fibrosis and asthma; provision of medical information and services in the field of respiratory conditions and disease, namely, chronic obstructive pulmonary disease, cystic fibrosis and asthma

Additional Information

Design Mark
The mark consists of two swoosh designs. The top swoosh extends from the upper left to the lower right with an upward curve, and the bottom swoosh extends from the lower right curving upward to the middle left, with a downward curve. The upper curve has a gray edge with colored gradations to gray blue and blue in the middle of that curve. The bottom curve has gray for an outside edge with colored gradations to blue gray in the middle of that curve.
Color Claim
The color(s) gray, blue gray and blue is/are claimed as a feature of the mark.

Classification

International Classes
005 042 044